American Association for Cancer Research

Poster Session B

Poster Session B
Monday, March 1
6:30 p.m.-8:30 p.m.

Subject to change (in alphabetical order, not board assignment order)

  • A cell-based small molecule screening assay against EMT in carcinoma. Kian-Ngiap Chua1, Victor Racine2, Ma Jing2, Wen-Jing Sim2, May-Ann Lee1, Jean-Paul Thiery2. 1Experimental Therapeutics Centre, Singapore, 2Institute of Molecular and Cell Biology, Singapore.
  • A transcriptome-wide analysis of gene expression and alternative splicing during EMT. Irina M. Shapiro1, Albert W. Cheng2, Nicholas Flytzanis2, Maja H. Oktay3, John S. Condeelis4, Christopher B. Burge2, Frank B. Gertler1. 1Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, 2MIT, Cambridge, MA, 3Montefiore Medical Center, Bronx, NY, 4Albert Einstein College of Medicine, Bronx, NY.
  • Autophagy is functionally required for EMT during RasV12 transformation. Candia Kenific, Rebecca Lock, Jayanta Debnath. University of California, San Francisco, San Francisco, CA.
  • Brachyury is a potential target for immunotherapeutic interventions aimed at eliminating invasive human tumor cells. Duane H. Hamilton, Romaine Fernando, Mary Litzinger, Bruce Huang, Kwong-Yok Tsang, Jeffery Schlom, Claudia Palena. Laboratory of Tumor Immunology and Biology, CCR, NCI, Bethesda, MD.
  • Comprehensive determination of an ESRP-regulated epithelial splicing network that is suppressed during the epithelial-mesenchymal transition. Claude C. Warzecha1, Shihao Shen2, Karine Amirikian1, Peng Jiang2, Yi Xing2, Russ P. Carstens1. 1University of Pennsylvania School of Medicine, Philadelphia, PA, 2University of Iowa, Iowa City, IA.
  • Cross-species expression profiling identifies genes differentially modulating the epithelial-mesenchymal transition program and cell migration/invasion capability. Haijun Zhang1, Sherwin Wu1, Feng Wu2, Stephen P. Ethier1, Fred Miller1, Guojun Wu1. 1Karmanos Cancer Institute, Wayne State University, Detroit, MI, 2Johns Hopkins University School of Medicine, Baltimore, MD.
  • DNAJB6 maintains epithelial phenotype. Rajeev S. Samant, Aparna Mitra, Mitchell Menezes, Lalita A. Shevde. Mitchell Cancer Institute, University of South Alabama, Mobile, AL.
  • EMT-induced tubulin detyrosination can be inhibited with parthenolide, reducing microtentacles and the lung retention of circulating breast tumor cells. Rebecca A. Whipple1, Michael A. Matrone1, Keyata Thompson1, Edward H. Cho1, Eric M. Balzer1, Kimberly C. Tuttle1, Michele I. Vitolo1, Jennifer R. Yoon1, Olga B. Ioffe1, Jing Yang2, Stuart S. Martin1. 1University of Maryland, Baltimore, MD, 2University of California, San Diego, La Jolla, CA.
  • ERG overexpression induces EMT in prostatic epithelial cells in an integrin-linked kinase (ILK)-dependent manner. Daiana Becker Santos1, Arusha Oloumi2, Paul C. McDonald2, Yubin Guo3, Michael E. Cox3, Shoukat Dedhar2. 1University of British Columbia, Vancouver, BC, Canada, 2British Columbia Cancer Research Centre, Vancouver, BC, Canada, 3The Prostate Centre at Vancouver General Hospital, Vancouver, BC, Canada.
  • Expression of cancer stem cell markers in malignant pleural mesothelioma. Svenja Thies1, Isabelle Opitz2, Daniela Mihic-Probst1, Walter Weder2, Holger Moch1, Alex Soltermann1. 1Institute of Surgical Pathology, Zürich, Switzerland, 2Clinic of Thoracic Sugery, Zürich, Switzerland.
  • Expression of miR-200 family members and miR-10b in colorectal cancer liver metastases and primary tumors. Åsa Wallin1, Per Gullstrand2, Xiao-Feng Sun1, Per Sandstrom2. 1Linköping University, Linköping, Sweden, 2Linköping University Hospital, Linköping, Sweden.
  • Expression profiling of combined microarray datasets. Kevin J. Thompson1, Jennifer Weller1, Zahra Bahrani-Mostafavi1, Taghi Mostafavi1, David L. Tait2. 1University of North Carolina-Charlotte, Charlotte, NC, 2Carolinas Healthcare System, Charlotte, NC.
  • Fbw7 and Notch in mammary tumor dormancy and recurrence. Daniel Abravanel, Christopher Sterner, Tien-Chi Pan, George Belka, Lewis Chodosh. University of Pennsylvania, Philadelphia, PA.
  • FGF-2 accelerates TGF-β-induced epithelial-mesenchymal transition and promotes invasion of cancer cells. Masao Saitoh1, Takuya Shirakihara2, Kana Horiguchi2, Kohei Miyazono2. 1Yamanashi University, Yamanashi, Japan, 2Tokyo University, Tokyo, Japan.
  • House dust mite allergens potentiate epithelial to mesenchymal transition in vitro. Jill R. Johnson, Jonas Fuxe. Karolinksa Institute, Stockholm, Sweden.
  • Insurance against EMT: MiR-200c directly targets multiple nonepithelial genes. Erin N. Howe, Dawn R. Cochrane, Nicole S. Spoelstra, Jennifer K. Richer. University of Colorado at Denver, Anschutz Medical Campus, Aurora, CO.
  • Integrative analysis of epithelial to mesenchymal transition in development and breast cancers. Ian M. Overton. MRC Human Genetics Unit, Edinburgh, United Kingdom.
  • Integrin β3 compensates for integrin β1 in sustaining an EMT phenotype induced by TGF-β in malignant mammary epithelial cells. Jenny G. Parvani1, Amy J. Galliher-Beckley2, Michael K. Wendt1, William P. Schiemann1. 1University of Colorado Denver, Aurora, CO, 2National Institutes of Health, Research Triangle Park, NC.
  • Is MUC1 involved in renal epithelial mesenchymal transition? Viviane Gnemmi, Audrey Bouillez, Laurent Zini, Brigitte Hemon, Nicole Porchet, Isabelle Van Seuningen, Xavier Leroy, Michael Perrais, Sebastien Aubert. INSERM U837, Lille, France.
  • KSHV induces endothelial to mesenchymal transition of lymphatic endothelial cells. Fang Cheng1, Simonas Laurinavicius1, Nami Sugiyama1, Chris Boshoff2, Kari Alitalo1, Kaisa Lehti1, Päivi M. Ojala1. 1University of Helsinki, Helsinki, Finland, 2University College London, London, United Kingdom.
  • Lysyl oxidase enhances EMT and oncogenic signaling by TGF-beta in normal and malignant mammary epithelial cells. Molly A. Taylor1, Jay Amin1, Dawn A. Kirschmann2, William P. Schiemann1. 1University of Colorado Denver, Aurora, CO, 2Northwestern University, Chicago, IL.
  • Matrix metalloproteinase-9 expression is required for tumor-promoting TGF-β signaling and tumorigenesis in aggressive breast cancer cells. Tressa M. Allington, Courtney von Bergen, William P. Schiemann. University of Colorado Denver, Anschutz Medical Campus, Aurora, CO.
  • Mdm2 is induced as cells undergo EMT and correlates with invasive late-stage breast cancer. Jacob Eitel1, Shinako Akaki2, Karen E. Pollok1, David A. Boothman2, Lindsey D. Mayo1. 1Indiana University, Indianapolis, IN, 2UT Southwestern, Dallas, TX.
  • Mena isoform expression, a marker for EMT, is correlated with TMEM count, a predictor of metastatic outcome, in human invasive ductal carcinoma of the breast. Maya Oktay1, Sumanta Goswami2, Brian D. Robinson3, Andrew Friedman2, Ester Adler1, Jason Moss1, Frank Gertler4, John Condeelis5, Joan G. Jones6. 1Montefiore Medical Center, Bronx, NY, 2Yeshiva University, New York, NY, 3The Johns Hopkins Hospital, Baltimore, MD, 4Massachusetts Institute of Technology, Cambridge, MA, 5Albert Einstein College of Medicine, Bronx, NY, 6Weill Cornell Medical College, New York, NY.
  • Mena isoform overexpression modulates epidermal growth factor receptor dynamics. Shannon K. Alford1, Erika Batchelder2, Hyung-Do Kim1, Laila Ritsma3, Devrim Pesen4, John Condeelis4, Jacco van Rheenen3, Defne Yarar2, Douglas Lauffenburger1, Frank Gertler1. 1MIT, Cambridge, MA, 2Whitehead/MIT, Cambridge, MA, 3Hubrecht Institute-KNAW and Academic Medical Center, Utrecht, The Netherlands, 4Albert Einstein College of Medicine, Bronx, NY.
  • Mena isoform status is associated with EMT and metastasis in mouse mammary tumors. Evanthia T. Roussos1, Yarong Wang1, Jeffery B. Wyckoff1, Michele Balsamo2, Sun Daqian1, Maja Oktay3, Cristina Ghiuzeli1, Maryland Rosenfeld-Franklin4, Sumanta Goswami5, Frank B. Gertler2, John S. Condeelis1. 1Albert Einstein College of Medicine, Bronx, New York, 2Massachuessets Institute of Technology, Cambridge, MA, 3Montefiore Medical Center, New York, New York, 4(OSI) TM Pharmaceuticals, Boulder, CO, 5Yeshiva University, New York, NY.
  • Mesenchymal-to-epithelial transition (MET): The bottleneck of prostate cancer progression in the bone marrow. Beatrice S. Knudsen1, Aaron Putzke1, Alexander Bailey1, Canan Akture1, John Opoku-Ansah1, Aviva Ventura1, Colm Morrissey2, Robert Vessella2. 1Fred Hutchinson Cancer Research Center, Seattle, WA, 2Univeristy of Washington, Seattle, WA.
  • Modeling the metastasis promoting tumor microenvironment using extracellular matrix three-dimensional culture. Hong Tuyet Nguyen1, Cui Li1, Stephen P. Kantrow2, Gilbert F. Morris3, Deborah E. Sullivan1, Bin Shan1. 1Tulane University School of Medicine, New Orleans, LA, 2Louisiana State University Health Sciences Center, New Orleans, LA, 3Tulane University Health Sciences Center, New Orleans, LA.
  • MT1-MMP/FGFR4 axis regulates tumor invasion by coupling FGF-signaling to pericellular proteolysis. Nami Sugiyama1, Markku Varjosalo1, Pipsa Meller1, Marko Hyytiäinen1, Sami Kilpinen1, Signe Ingvarsen2, Lars Engelholm2, Olli Kallioniemi1, Jouko Lohi3, Kari Alitalo1, Jussi Taipale1, Jorma Keski-Oja1, Kaisa Lehti1. 1University of Helsinki, Helsinki, Finland, 2Rigshospitalet, Copenhagen, Denmark, 3Helsinki University Hospital, Helsinki, Finland.
  • Murine epithelial cells develop EMT phenotype when spontaneously transformed. Hesed Maria Padilla-Nash, Nicole E. McNeil, Tri Nguyen, Thomas Ried. National Cancer Institute, Bethesda, MD.
  • Neuropilin-2 is downregulated by Snail during EMT in lung cancer. Patrick Nasarre, Vincent Potiron, Joyce Nair-Menon, Robert Gemmill, Joelle Roche and Harry Drabkin. Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC.
  • New insight into the function of Mena11a, a Mena isoform downregulated during epithelial to mesenchymal transition. Michele Balsamo1, Irina Shapiro1, Dorothy A. Schafer2, John S. Condeelis3, Frank B. Gertler1. 1Massachusetts Institute of Technology, Koch Institute for Integrative Cancer Research, Cambridge, MA, 2University of Virginia, Charlottesville, VA, 3Albert Einstein College of Medicine, Bronx, NY.
  • NRAGE interactions with TBX2 and ankyrin-G: A pathway for the control of anoikis by E-cadherin and EMT. Steven M. Frisch1, Sanjeev Kumar1, Ryan Ice1, Jane Schupp1, Sun Park1, Elizabeth Killiam2, David L. Rimm2. 1West Virginia University, Morgantown, WV, 2Yale University, New Haven.
  • Nrf2 regulates cancer cell motility and morphology through regulation of Smad signaling. Girish Rachakonda, Konjeti R. Sekhar, Dawit Jowhar, Phillip C. Samson, John P. Wikswo, R. Daniel Beauchamp, Pran K. Datta, Michael L. Freeman. Vanderbilt, Nashville, TN.
  • Osteopontin promotes CCL5 (RANTES) expression in mesenchymal stromal cells. Victoria M. Kim, Zhiyong Mi, Hongtao Guo, Syamal D. Bhattacharya, Paul C. Kuo. Duke University, Durham, NC.
  • Snail cooperates with KrasG12D in a gene dose-dependent fashion to accelerate pancreatic ductal adenocarcinoma progression in genetically engineered mice. Mariel C. Paul1, Barbara Seidler1, Angelika Schnieke2, Roland M. Schmid1, Guenter Schneider1, Dieter Saur1. 1Technische Universität München, Klinikum rechts der Isar, Medizinische Klinik, München, Germany, 2Technische Universität München, Livestock Biotechnology, München, Germany.
  • Sphingosine-1-phosphate triggers cell extrusion and promotes apoptosis in epithelia. Yapeng Gu, Jody Snow Rosenblatt. Huntsman Cancer Institute, Salt Lake City, UT.
  • Studying the epithelial to mesenchymal transition utilizing a TGFβ-inducible lung cancer xenograft model. Joseph S. Krueger1, Gretchen Argast2, Krista Campbell1, Matthew O'Connor2, Stacia Silva1, Regina Sennello1, Stuart Thomson2, David G. Young1, David Epstein2, Robert Wild1, Maryland Rosenfeld-Franklin1. 1OSI Pharmaceuticals, Boulder, CO, 2OSI Pharmaceuticals, Farmingdale, NY.
  • Targeted inhibition of Snail family zinc finger transcription factors by an oligonucleotide-Co(III) Schiff base conjugate. Allison S. Harney, Carole LaBonne, Thomas J. Meade. Northwestern University, Evanston, IL.
  • TGFβ, BMP, and TCF signaling are associated with EMT in a Pten/P53 null mouse model of prostate cancer. Yen-Nien Liu, Philip Lloyd Martin, Ivy (Juanjuan) Yin, Wassim Gergy Abou-Kheir, Paul Hynes, Orla Casey, Rachel Pierce, Lei Fang, Kathleen Kelly. National Cancer Institute, Bethesda, MD.
  • TGF-β1 promotes targeted migration of tumor cells to lymphatics via the CCR7/CCL21 pathway. Mei-Fong Pang, Jonas Fuxe. Karolinska Institutet, Stockholm, Sweden.
  • The combined loss of Lkb1 and PTEN in the mouse bladder causes tumorigenesis and epithelial-mesenchymal transition. Boris Y. Shorning, David Griffiths, Alan R. Clarke. Cardiff University, Cardiff, United Kingdom.
  • The effect of withaferin-A and related analogs on breast cancer migration and invasion. Laura M. Bender, Thota Ganesh, Katherine Hales, James Snyder, Dennis Liotta, Adam Marcus. Emory University, Atlanta, GA.
  • The EMT-inducing protein S100A4 increase mammary gland branching morphogenesis. Kristin Andersen1, Hidetoshi Mori2, Jimmie E. Fata3, Tove R. Oyjord1, Gunhild M. Malandsmo1, Mina J. Bissell2. 1Oslo University Hospital, Radiumhospital, Oslo, Norway, 2Lawrence Berkeley National Laboratory, Berkeley, CA, 3City University of New York, New York, NY.
  • The endocytic protein epsin regulates cancer cell migration and invasion through an endocytosis-independent mechanism. Brian G. Coon, Timothy L. Ratliff, R. Claudio Aguilar. Center for Cancer Research, Purdue University, West Lafayette, IN.
  • The role of HMGA2 in cancer stem cells. Else Munthe, Eva Wessel Stratford, Silje Lauvrak, Anna Wennerstrøm, Ola Myklebost. Norwegian Radiumhospital, Oslo, Norway.
  • The role of the microRNA-200 family in Zeb1-induced epithelial-mesenchymal transition and metastases in a p53/K-ras murine model of lung adenocarcinoma.  Zain H. Rizvi1, Don L. Gibbons2, Creighton J. Chad3, Phillip A. Gregory4, Jon M. Kurie2. 1Howard Hughes Medical Institute, UT M. D. Anderson Cancer Center, Houston, TX, 2UT M. D. Anderson Cancer Center, Houston, TX, 3Baylor College of Medicine, Houston, TX, 4Institute of Medical and Veterinary Science, Adelaide, SA, Australia.
  • The role of the miR-106b-25 cluster in Six1-mediated breast cancer metastasis. A.L. Smith, D.S. Micalizzi, D.J. Drasin, H.L. Ford. Molecular Biology Program, University of Colorado Denver, Aurora, CO.
  • The T-box transcription factor Brachyury induces epithelial to mesenchymal transition in human epithelial tumor cells. Romaine Fernando, Mary Litzinger, Duane Hamilton, Bruce Huang, Jeffrey Schlom, Claudia Palena. National Cancer Institute, Bethesda, MD.
  • The transcription factor C/EBPβ is a positive regulator of junction proteins and a negative regulator of the epithelial-mesenchymal transition in breast epithelial cells. Joel Johansson, Tove Berg, Jonas Fuxe. Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
  • Tissue inhibitor of metalloproteinase 2 (TIMP-2), a negative regulator of EMT in A549 cells. Dimitra Bourboulia, Sandra Jensen-Taubman, Biju Issac, Uma Shankavaram, William G. Stetler-Stevenson. National Cancer Institute, Bethesda, MD.
  • TMPRSS2:ERG Gene-fusion promotes epithelial to mesenchymal transition in immortalized human prostate epithelial cells. Orit Leshem1, Madar Shlomi2, Ira Kogan2, Naomi Goldfinger2, Varda Rotter2, Shmuel Ben-Sasson1, Raanan Berger3. 1IMRIC, The Hebrew University-Hadassah Medic, Jerusalem, Israel, 2Weizmann Institute of Science, Rehovot, Israel, 3Sheba Cancer Research Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
  • ZEB1 represses laminin-332 and β4 integrin expression in prostate cancer cells: A connection between EMT and cooperative cell migration? Justin M. Drake, J. Matthew Barnes, Christopher S. Stipp, Michael D. Henry. University of Iowa College of Medicine, Iowa City, IA.